Apixaban Renal Clearance Dose
For atrial fibrillation, prescribe apixaban 5 mg twice daily for most patients; reduce to 2.5 mg twice daily only when the patient meets at least TWO of three criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL. 1
Standard Dosing Algorithm
The FDA-approved dose for stroke prevention in atrial fibrillation is 5 mg orally twice daily. 1
Dose reduction to 2.5 mg twice daily requires meeting ≥2 of the following three criteria simultaneously:
Meeting only ONE criterion does NOT justify dose reduction—this is the most common prescribing error with apixaban. 2, 3
Renal Function-Based Dosing
Calculate Creatinine Clearance with Cockcroft-Gault
- Always use the Cockcroft-Gault equation with actual body weight to calculate creatinine clearance (CrCl)—do NOT use eGFR for apixaban dosing decisions, as the pivotal trials and FDA labeling relied on Cockcroft-Gault. 2, 4
Dosing by CrCl Category
| CrCl (mL/min) | Recommended Dose | Key Points |
|---|---|---|
| >30 | 5 mg twice daily (unless ≥2 reduction criteria met) | Standard dosing for moderate CKD [2,1] |
| 15–29 | 2.5 mg twice daily (mandatory for ALL patients) | Severe renal impairment overrides the "2-of-3" rule [2,5] |
| <15 or dialysis | 5 mg twice daily; reduce to 2.5 mg twice daily if age ≥80 years OR weight ≤60 kg (only ONE criterion required) | FDA-approved for stable hemodialysis [2,6] |
For CrCl 30–59 mL/min (CKD stage 3), use the standard 5 mg twice daily dose unless the patient meets ≥2 of the three dose-reduction criteria. 2, 4
For CrCl 15–29 mL/min (CKD stage 4), prescribe 2.5 mg twice daily to ALL patients regardless of age or weight—severe renal impairment alone mandates dose reduction. 2, 5
For CrCl <15 mL/min or dialysis (CKD stage 5/ESRD), the FDA recommends 5 mg twice daily, reduced to 2.5 mg twice daily if EITHER age ≥80 years OR weight ≤60 kg is present (only one criterion needed in dialysis). 2, 6
Pharmacokinetic Rationale
Apixaban has only 27% renal clearance, making it the safest direct oral anticoagulant for patients with renal impairment compared to dabigatran (≈80% renal) or rivaroxaban (≈66% renal). 2, 6, 4
This low renal dependence provides a wider safety margin as kidney function declines and makes apixaban the preferred DOAC in advanced CKD. 2, 7
Evidence Supporting Dose-Reduction Criteria
The ARISTOTLE trial demonstrated that patients receiving the reduced dose of 2.5 mg twice daily (when meeting ≥2 criteria) had similar efficacy and safety profiles compared to warfarin. 2, 8
Patients with only ONE dose-reduction criterion who received 5 mg twice daily showed consistent benefit versus warfarin for both stroke prevention and bleeding reduction, with no increased risk. 2, 3
In patients with severe CKD (CrCl 15–29 mL/min), apixaban 5 mg twice daily was associated with higher bleeding risk compared to 2.5 mg twice daily, with no difference in stroke/systemic embolism or death, supporting mandatory dose reduction in this population. 5
Monitoring Requirements
Reassess renal function at least annually in all patients on apixaban. 2
Increase monitoring frequency to every 3–6 months when CrCl <60 mL/min or if clinical deterioration occurs (acute illness, infection, heart failure exacerbation). 2, 6
No routine INR or coagulation monitoring is required for apixaban therapy. 2
Drug Interaction-Driven Dose Adjustments
Reduce apixaban from 5 mg to 2.5 mg twice daily when co-administered with BOTH a P-glycoprotein inhibitor AND a strong CYP3A4 inhibitor (e.g., ketoconazole, ritonavir, itraconazole). 2, 1
Avoid apixaban entirely with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) as they markedly reduce apixaban levels. 2
Common Prescribing Pitfalls
Inappropriate dose reduction based on a single criterion occurs in 9.4–40.4% of prescriptions—do NOT reduce the dose based solely on age <80 years, weight >60 kg, or isolated moderate renal impairment (CrCl 30–59 mL/min). 2
Do NOT use eGFR for dosing decisions; always calculate CrCl with Cockcroft-Gault using actual body weight. 2, 4
For patients with CrCl 15–29 mL/min, the 2.5 mg twice daily dose is mandatory regardless of the "2-of-3" criteria. 2, 5
In dialysis patients, only ONE criterion (age ≥80 OR weight ≤60 kg) is required to reduce from 5 mg to 2.5 mg twice daily—this differs from the standard "2-of-3" rule. 2, 6
Special Populations
End-Stage Renal Disease / Dialysis
Apixaban is the only DOAC with FDA approval for stable hemodialysis patients; dabigatran and edoxaban are contraindicated in dialysis. 6, 4
The FDA-approved dose is 5 mg twice daily, reduced to 2.5 mg twice daily if age ≥80 years OR weight ≤60 kg (only one criterion required). 2, 6
Recent observational data suggest standard-dose apixaban (5 mg) may have lower stroke/embolism risk than low-dose (2.5 mg) in dialysis patients, though bleeding risk must be carefully weighed. 6